Want to see RVTY full AI Analyst Report?
RVTY Stock Chart & Stats
$93.96
-$0.88(-0.75%)
At close: 4:00 PM EST
$93.96
-$0.88(-0.75%)
Day’s Range― - ―
52-Week Range$81.22 - $118.30
Previous CloseN/A
Volume176.09K
Average Volume (3M)1.31M
Market Cap
$12.29B
Enterprise Value$12.44K
Total Cash (Recent Filing)$860.32M
Total Debt (Recent Filing)$3.35B
Price to Earnings (P/E)50.7
Beta0.95
Next Earnings
Aug 04, 2026EPS Estimate
1.21Next Dividend Ex-DateN/A
Dividend Yield0.26%
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,559,780
10 Day Avg. Volume1,092,134
30 Day Avg. Volume1,310,645
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$110.25Price Target Upside17.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)5.24
Revenue Forecast (FY)$2.83B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Services ModelRevvity's mix of capital instruments and high-frequency consumables, plus software and services, creates a durable annuity-like revenue stream from its installed base. This recurring mix supports predictable cash flow, higher lifetime customer value, and resilience across research and clinical cycles.
Strong Absolute Free Cash FlowMaterial TTM free cash flow in the high hundreds of millions provides lasting financial flexibility to fund R&D, tuck-in M&A, opportunistic buybacks, and debt paydown. Even if growth moderates, durable cash generation underpins strategic initiatives and capital allocation over the medium term.
High-growth Software / SaaS ARRRapid SaaS/ARR expansion shifts Revvity's mix toward higher-margin, sticky recurring revenue. Software growth improves revenue visibility, cross-sell economics and margin scalability over time, helping smooth cyclical instrument demand and bolstering long-term profitability.
Bears Say
Weakened Returns And Earnings VolatilityReturn metrics have deteriorated compared with pre-2022 levels and ROE near 3% signals limited efficiency in deploying shareholder capital. Historical earnings volatility, including a 2023 loss, suggests structural challenges in restoring prior margin/return profiles over the medium term.
China Diagnostics Divestiture & Timing RiskDivesting the China immunodiagnostics unit is structural but introduces execution and timing risk: proceeds aren't realized until close, near-term EPS is reduced, and regulatory hurdles or delays could disrupt projected margin and cash-flow benefits the company expects from the strategic portfolio shift.
Weaker Cash-conversion TrendsA sustained decline in operating-cash-to-net-income conversion points to working-capital pressure or collection issues. If persistent, weaker cash conversion can limit reinvestment, reduce the pace of buybacks/debt reduction, and constrain the company's ability to fund growth without altering capital allocation.
Revvity News
RVTY FAQ
What was Revvity, Inc.’s price range in the past 12 months?
Revvity, Inc. lowest stock price was $81.22 and its highest was $118.30 in the past 12 months.
What is Revvity, Inc.’s market cap?
Revvity, Inc.’s market cap is $12.29B.
When is Revvity, Inc.’s upcoming earnings report date?
Revvity, Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were Revvity, Inc.’s earnings last quarter?
Revvity, Inc. released its earnings results on May 05, 2026. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.016 by $0.024.
Is Revvity, Inc. overvalued?
According to Wall Street analysts Revvity, Inc.’s price is currently Undervalued.
Does Revvity, Inc. pay dividends?
Revvity, Inc. pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.26%. See more information on Revvity, Inc. dividends here
What is Revvity, Inc.’s EPS estimate?
Revvity, Inc.’s EPS estimate is 1.21.
How many shares outstanding does Revvity, Inc. have?
Revvity, Inc. has 111,559,780 shares outstanding.
What happened to Revvity, Inc.’s price movement after its last earnings report?
Revvity, Inc. reported an EPS of $1.04 in its last earnings report, beating expectations of $1.016. Following the earnings report the stock price went up 6.694%.
Which hedge fund is a major shareholder of Revvity, Inc.?
Currently, no hedge funds are holding shares in RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$110.25 (17.34% Upside)
$110.25 (17.34% Upside)
Blogger Sentiment
Bullish
RVTY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 76.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.44%
12-Months-Change
Fundamentals
Return on Equity
0.26%
Trailing 12-Months
Asset Growth
-2.95%
Trailing 12-Months
Company Description
Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
RVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$110.25
▲(17.34% Upside)
Technical Analysis
Ownership Overview
0.46% Insiders
58.55% Mutual Funds
1.35% Other Institutional Investors
13.15% Public Companies and
Individual Investors